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Summary 
The  immune  system can  recognize  differentiation  antigens  that  are  selectively  expressed  on 
malignant cells and their normal cell counterparts.  However, it is uncertain whether immunity 
to differentiation antigens can effectively lead to tumor rejection. The mouse brown locus pro- 
tein,  gp75 or tyrosinase-related protein  1, is a melanocyte differentiation antigen expressed by 
melanomas and normal melanocytes. The gp75 antigen is recognized by autoantibodies and au- 
toreactive  T  cells  in persons with  melanoma.  To  model autoimmunity  against a  melanocyte 
differentiation  antigen,  mouse  antibodies  against  gp75 were passively transferred  into  tumor- 
bearing mice. Passive immunization with a mouse monoclonal antibody against gp75 induced 
protection  and  rejection  of both  subcutaneous  tumors  and  lung  metastases  in  syngeneic 
C57BL/6 mice, including established tumors. Passive immunity produced coat color alterations 
but  only  in  regenerating  hairs.  This  system provides  a  model  for  autoimmune  vitiligo  and 
shows that immune responses to melanocyte differentiation antigens can influence mouse coat 
color. Immune recognition of a melanocyte differentiation antigen can reject tumors, provid- 
ing a basis for targeting tissue autoantigens expressed on cancer. 
E 
xperimental  evidence  shows  that  the  immune  system 
can recognize antigens  expressed by cancer cells.  Re- 
cently, the isolation of genes encoding cancer antigens has 
led  to  the  identification  of these  molecules  (1-3).  From 
these  studies,  a  paradigm  emerges  in  which  the  immune 
repertoire recognizes a set of self-antigens, termed differen- 
tiation  antigens,  expressed  by malignant  cells  but  also  by 
their normal cell counterparts (3-5). 
The  immune  response  to  melanoma  has  been  studied 
more  extensively  than  that  to  any  other  human  cancer. 
Dissection  of  the  immune  response  to  melanoma  has 
shown  that  differentiation  antigens  expressed  by  normal 
melanocytes  and  related  neuroectoderm-derived  cells  are 
dominant  antigens  recognized by the  immune  system  (3, 
5-16).  Among the  best-characterized  melanoma  autoanti- 
gens  are proteins  of the  tyrosinase family.  Tyrosinase  (the 
product of the albino locus) is the prototype molecule, and 
other members include gp75 or tyrosinase-related protein 1 
(the product of the brown locus)  and gpl00  (the presumed 
product of the silver locus)  (17-19).  These molecules, plus 
the  MelanA/MART-1  antigen,  are  all  melanocyte-specific 
molecules recognized by the immune system of melanoma 
patients  (8,  9,  11-16).  The  question  of whether  immune 
recognition of self (differentiation antigens)  can lead to tu- 
mor rejection  arises.  In particular,  we considered whether 
immunity to melanocytes can actually lead to rejection  of 
melanoma,  and whether  there  are  sequelae  in  normal  tis- 
sues that contain melanocytes. 
Materials and Methods 
Mice and  Tumors.  C57BL/6  (6-8 wk-old females) were ob- 
tained from The Jackson Laboratory (Bar Harbor, ME). B16F10 
is  a mouse melanoma  cell line  of C57BL/6  origin kindly pro- 
vided  by  Dr.  Isaiah  Fidler  (M.D.  Anderson  Cancer  Center, 
Houston,  TX)  (20). B78H.1  is a variant of B16 melanoma that 
does not express  the gp75  antigen.  JBtKH is a melanoma from 
C57BL/6 provided, by Dr. P. Livingston (Memorial Sloan-Ket- 
tering,  NY). Other tumors derived from C57BL/6 mice include 
the  RMA  and  EL-4  lymphomas,  Lewis  lung  carcinoma,  and 
MC58  sarcoma  (from  Dr.  J.  Nicolic-Zugic,  Memorial  Sloan- 
Kettering,  NY). All animal  experiments and care were in accor- 
dance with institutional  guidelines. 
For subcutaneous tumors, tumor cells were injected subcuta- 
neously in  the  mouse flank.  B16F10  melanoma  cells (5  ￿  104 
cells), B78H.1, 1KMA, EL-4, JB1KH, and Lewis lung carcinoma 
(104-106 cells) were injected subcutaneously in 0.1 ml normal sa- 
line  into  the  flank  of syngeneic C57BL/6  mice.  Tumors were 
checked at least four times per week by palpation and inspection. 
For each tumor type, palpable  tumors formed in  10-21  d.  For 
B16F10 melanoma lung metastases, C57BL/6 mice were injected 
intravenously through the tail vein with  1 X  10  s B16F10 mela- 
noma cells in sterile saline. For depilation  experiments,  C57BL/6 
mice were depilated  on the day before starting treatment over the 
posterior flank and observed for coat color. The same results were 
observed if the  coat was  plucked manually under anesthesia  or 
depilated  with hair remover (JMC, Inc., Tokyo). 
Mice were treated intraperitoneally  with mAb TA99 or con- 
trol mouse IgG2a mAb UPC10 diluted in 0.3-0.4 ml of normal 
saline. TA99 mAb was purified from mouse ascites by protein A 
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by digestion with pepsin and purification over protein A Sepharose 
(Pharmacia Biotech, Inc., Piscataway, NJ).  Control IgG2a mAb 
UPC10  was from Sigma Chemical Co.  (St. Louis, MO).  Injec- 
tion with control mAb UPC10 did not induce any difference in 
growth of B16F10 melanoma compared with untreated control 
mice. For subcutaneous tumor measurements, the longest surface 
length (a) and its perpendicular width (b) were measured, and tu- 
mor size reported as a X  b. For lung metastases,  at 16-20 d after 
tumor  challenge, mice  were  killed and  surface  lung metastases 
were scored and counted as black nodules under a dissecting mi- 
croscope. Surface lung metastases were detected by day 4-7 under 
a dissecting microscope and by day 7-10 by eye. For histologic 
evaluation, tissues  and tumors  were  fixed in  formalin solution, 
blocked in paraffin,  sectioned every 4  g,m, and stained with he- 
matoxylin and eosin. Statistical analysis oftunlor growth was per- 
formed using the Student's t test or Bonferroni two-sided t test, a 
conservative analysis to allow for multiple comparisons. 
Antibody  Treatments  In  Vivo.  Depletion ofT cells in vivo was 
accomplished by intraperitoneal administration of  rat mAb GK1.5 
(anti-CD4;  IgG2b)  and  mAb  2.43  (anti-CD8;  IgG2b),  and 
Thyl.2 + cells by mAb 30-H12  (produced by hybridomas from 
the American Type Culture Collection, Rockville, MD). These 
mAbs were used as ascites fluids (titer >1 : 10,000  by staining of 
mouse  thymocytes by flow cytometry), mAb preparations  (0.2 
ml)  were  injected  intraperitoneally at  day  -3  and  every  7  d 
thereafter.  Throughout  experiments,  these  treatments  depleted 
respective T  cell subpopulations and Thy-1 + populations >97% 
as determined by indirect immunofluorescence staining and cyto- 
fluorometric analysis of lymph nodes and thymocytes with mAbs 
GK1.5  (CD4),  2.43  (CD8),  or 30-H12  (Thyl.2). Natural killer 
(NK) cell depletion was performed using mAb PK136 (anti-NK- 
1.1) (American Type Culture Collection). Antibody (0.2 ml) was 
injected intraperitoneally at day -3 and every 7 d thereafter. De- 
pletion of NK cells was assessed by 4-h SlCr-release assays with 
5,000  YAC  cells  as  targets and  spleen  cells  as  effector cells  at 
effector-to-target ratios of 100: 1,  50: 1,  and  25: 1,  and  deple- 
tion was shown to abrogate completely detectable NK activity. 
For depletion of complement,  mice  were  injected intraperito- 
neally with 10 U  cobra venom factor (Diamedix Corp., Miami, 
FL)  on  day  -1  and  every 4  d.  Depletion  of complement  in 
sera of treated mice was verified using lysis of sensitized rabbit 
RBC (21). 
Expression  of  gp 7  5 Antigen on B16F I O Melanoma.  Intracellular 
expression of gp75 was determined using mAb TA99 in indirect 
immunofluorescence assays against B16F10 melanoma cells fixed 
and permeabilized in methanol/acetone (1 : 1) at 4~  for 15 rain. 
Intracellular expression was  confirmed by immunoelectron mi- 
croscopy using protein A-labeled colloidal gold particles as de- 
scribed (22).  Cell-surface expression was  shown  by binding of 
mAb TA99 to intact, live B16F10 cells by enzyme-linked immu- 
noassay  (titer >1/t0,000)  and by protein A-ms  hemadsorp- 
tion assay (titer >1/5,000)  (5, 22). 
recognized on  melanomas  by both  autoantibodies and  au- 
toreactive T  cells (8,  9).  The  mouse  mAb TA99  binds to 
both human and mouse gp75 and reacts with normal mel- 
anocytes and melanoma but does not react with other tis- 
sues (22). TA99 mAb has been shown to localize efficiently 
to melanoma xenografts in mice  (tumor/normal  tissue ra- 
tios  >100 : 1 to  10  s : 1),  showing that systemic administra- 
tion of antibody against gp75 can specifically localize to tu- 
mor sites (23). 
The  gp75 +  B16F10  melanoma  is  a  spontaneously aris- 
ing tumor that is very weakly immunogenic  in syngeneic 
C57BL/6  mice.  B16F10  cells  from  fresh  tumors  express 
gp75 in melanosomes within the cell and on the cell surface 
(see Materials and Methods). Incubation of rnAb TA99 (up 
to 600 ~g/ml for 7 d) with B16F10 melanoma cells in vitro 
did not affect the  cell growth,  morphology, or pigmenta- 
tion.  Mice  were  challenged  subcutaneously  with  B16F10 
melanoma and  treated with either mAb TA99 or isotype- 
matched control mAb UPC10.  With this tumor challenge, 
B16F10  uniformly forms palpable tumors  in ~2  wk.  Tu- 
mors  were  rejected in  mice  treated with  mAb  TA99  but 
not  in  control  mice  (Fig.  1).  Protection  against  tumor 
growth was  observed with  doses of mAb TA99  as low as 
37.5  Ixg,  but  optimal  protection  was  seen  with  doses  of 
150/~g mAb TA99  (Fig. 2).  Tumor protection was ob- 
served beyond 50-70 d. 
This  antitumor  effect  was  specific  for  tumors  that  ex- 
pressed gp75  antigen.  Tumor  protection was  seen  for the 
gp75 +  JBRH  melanoma  after  subcutaneous  challenge  in 
syngeneic  C57BL/6  mice  (time  to  median  appearance  of 
tumors delayed by >31  d). However, no antitumor effects 
were observed in syngeneic C57BL/6  mice with a  gp75- 
variant of the parental B16 melanoma (B78H. 1 melanoma), 
nor with other subcutaneous gp75- tumors, including EL4 
lymphoma,  RMA  lymphoma,  Lewis  lung  carcinoma,  or 
MC58 sarcoma. 
Intravenous  injection  of B16F10  leads  reproducibly  to 
lung metastases (20, 24). Treatment with mAb TA99 mark- 
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Results  and  Discussion 
Syngeneic mouse tumor models were established to ex- 
amine  whether  immunity  against  antigens  expressed  on 
normal melanocytes and melanoma can lead to  tumor  re- 
jection. The brown locus product, gp75, was the target anti- 
gen in these models. The gp75 autoantigen is relevant because 
it is potentiany immunogenic  in  persons  with  melanoma, 
Figure 1.  Protective immunity induced by mAb TA99 against B16F10 
melanoma cells. Melanoma cells (5  X  104) were injected subcutaneously 
into the flank of C57BL/6 mice. Mice were treated intraperitoneally with 
(A) control mouse IgG2a mAb UPC10 or (B) mAb TA99, injected at a 
dose of 150 I~g (days 0, 2, 4, 7, 9, and 11). There were eight mice in each 
group.  Treatment  with  mAb TA99 produced  a significant increase (P 
<0.0001, Bonferroni two-sided t test) in proportion of tumor-free mice. 
Each symbol in A represents an individual mouse. In group B, eight mice 
were treated with mAb TA99, and only one mouse developed palpable 
tumor (0). 
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Figure  2.  Protective immunity 
by different doses of mAb TA99 
against B16F10 melanoma.  Mice 
were  treated  with  150  p,g  of 
control  mAb  UPC10  (0)  or 
mAb  TA99  at  150  I-~g ([]),  75 
p,g (4,), or 37.5 Izg (V) per dose 
as described in the legend of Fig. 
1. There were six to eight mice 
in each group. Mice were scored 
as tumor free  or tumor bearing, 
and  the  proportion  of  tumor- 
bearing  mice  (ratio  of tumor- 
bearing/total  number  of  mice 
per  group)  was  calculated  for 
each time point. 
edly reduced the number of lung surface metastases even at 
individual  doses  as  low  as  50  Izg (Fig.  3  A  and  data  not 
shown).  Injection of F(ab')2 fragments of mAb TA99  did 
not have any effect on the number of B16F10  metastases, 
supporting a crucial role for the Fc portion of mAb TA99 
in antitumor effects (data not shown). 
We  asked  whether  treatment  with  mAb  TA99  would 
have antitumor  effects in  established  metastases.  Delaying 
treatment with mAb TA99 for 2-7  d  after challenge with 
B16F10  still  induced  substantial  protection  against  me- 
tastases but required higher doses ofmAb  TA99 (P <0.001, 
paired  Student's  t  test  at  7  d)  (Fig.  3  B).  Effects  of mAb 
TA99  were  also  observed  on  growth  of  subcutaneous 
B16F10  melanoma  when  treatment  was  delayed  4  d  after 
tumor  challenge  (median  time to  appearance  of tumor in- 
creased by  14 d),  and slightly but reproducibly when treat- 
ment was delayed 7  d  (median time to appearance of tumor 
increased 6  d). 
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Figure  3.  Antitumor  effects 
of mAb TA99 on B16F10  lung 
metastases, including  established 
metastases. Syngeneic  C57BL/6 
mice were injected intravenously 
through  the  tail  vein  with 
B16F10  melanoma  cells. Mice 
were  treated  intraperitoneally 
with  control  mAb  UPC10  or 
mAb  TA99.  18  d  after  tumor 
challenge, mice were killed, and 
surface  lung  metastases  were 
scored. There were eight to nine 
mice  in  each  group.  (A)  mAb 
TA99 and control mAb UPC10 
were  administered  at  a  150-~g 
dose (days 0, 2, 4, 7, 9, and 11). 
(B) 600-~g doses ofmAb TA99 
were given three rimes per week 
for 2 wk starting on day 0  (6 h 
after  tumor  challenge),  day  2, 
day 4, or day 7; a 600-b~g dose of 
mAb UPC10 was given on days 
0, 2,  4, 7, 9, and  11. Error bars 
represent  1 SD. 
Histologic examination of residual B 16F 10 subcutaneous 
lesions  and  metastatic  lung  lesions  in  mice  treated  with 
mAb  TA99  showed  occasional  infiltration  of lymphocytes 
and  macrophages,  compared  with  no  mononuclear  or in- 
flammatory  infiltrates  observed  in  control  mice.  To  assess 
what  components  of the  immune  or inflammatory  system 
might be involved in  tumor rejection,  T  lymphocyte sub- 
sets,  complement,  or  NK  cell populations  were  depleted 
before  challenge  with  tumor  cells.  Depletion  of CD8 +  T 
cells and  complement  did  not  alter tumor  rejection medi- 
ated  by  mAb  TA99  (Fig.  4  shows  results  for  lung  me- 
tastases:  data  not shown  for subcutaneous  tumors).  Deple- 
tion of CD4 §  cells partially decreased rejection of B16F10 
lung metastases by mAb TA99  (Fig. 4)  (depletion ofCD4  + 
cells without mAb TA99 treatment did not affect the num- 
ber of B16F10  metastases;  data  not shown)  but  did not af- 
fect growth of subcutaneous  B16F10 tumors. 
Depletion of an NK1.1 + cell population appeared  to ab- 
rogate  the  protective  effect of mAb  TA99  in  both  meta- 
static B16F10 in the lung (Fig. 4) and subcutaneous B16F10 
tumors  (data not shown),  supporting  a  role for NK  cells in 
tumor rejection mediated by mAb TA99. NK1.1 + cells ap- 
pear to provide natural immunity against B16F10 lung me- 
tastases  (24).  We further examined the role ofNK1.1 + cells 
in the lung metastases  model (using the same  experimental 
design  described  in  Fig.  5  with  six  to  eight  mice  per 
group):  (a) Depletion ofNKl.1  + cells from C57BL/6  mice 
led  to  a  significant  increase  in  the  number  of metastases 
(mean 314  -+  58 metastases)  compared with control unde- 
pleted mice (136  -- 25 metastases);  (b)  treatment with mAb 
TA99  markedly decreased metastases  (12  __-  11  metastases); 
and  (c)  the number of lung metastases  in mice treated  with 
mAb  TA99  and  also  depleted of NKI.1 +  cells was  signifi- 
candy  greater  (mean  186  +  42)  than  in mice treated  with 
TA99  alone  (12  +  11),  but  not  as great  as  the  number  of 
metastases  in  untreated  NKl.l-depleted  mice  (314  +  58). 
These  results  suggested  that  other  components  of the  host 
in addition to NK  cells, such as CD4 + cells (Fig. 4),  partic- 
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Figure  4.  Evaluation  of potential 
effector  functions  in  rejection  of 
B16F10  lung metastases induced  by 
mAb TA99 (see legend of Fig. 3 for 
methods).  C57BL/6  mice  were 
challenged intravenously with mela- 
noma cells and treated  with 150-~g 
doses  of control  mAb  UPC10  or 
mAb TA99  (days 0, 2, 4, 7,  9,  and 
11).  Mice  were  killed  on  day  18. 
There  were  six to  seven  mice per 
group.  Depletion  of  CD4  +  and 
CD8 + T cell subsets in vivo was ac- 
comphshed  by  intraperitoneal  ad- 
ministration  of  rat  mAb  GK1.5 
(anri-CD4)  and  mAb  2.43  (anti- 
CD8).  NK  cell  depletion  was 
performed  using mAb PK1.36 (anti- 
NK-I.1).  For depletion  of comple- 
ment, mice were injected  intraperi- 
toneally  with  cobra  venom  factor 
(CVF). Error bars represent  1 SD. 
1611  Hara et al.  Brief Definitive Report ipated  in  rejection  of lung  metastases  mediated  by  mAb 
TA99.  It is possible that NKI.1 + cells binding mAb TA99 
through  Fc  receptors  secondarily  activated  CD4 +  cells  to 
participate in tumor rejection. Alternatively,  CD4 + T  cells 
might  be  activated  by  APC  through  internalization  and 
presentation of antigen-antibody complexes. 
Mice treated with mAb TA99 were examined for changes 
in  pigmentation  and  other  autoimmune-type  manifesta- 
tions.  The  coat  of animals  remained  black  unless  animals 
were  depilated  to  prepare  skin  sites  for  tumor  injection. 
Pigmented melanocytes on the trunk of adult mice are found 
in hair bulbs.  Regenerating  hairs  on the  trunk were  depig- 
mented in  13 of 13 tumor-bearing mice treated with mAb 
TA99 at 300-900  p~g per dose  (three times per week for 2 
wk) but not in mice treated with  control mAb UPC10  (0 
of 36 mice) or untreated control mice (0 of 30 mice). De- 
pigmentation  was  not  related  to  injection  of tumor  cells; 
treatment of depilated  C57BL/6 mice without injection of 
tumor  cells  still  led  to  depigmentation  in  12  of 12  mice 
treated with 300-1,000-1~g dose ofmAb TA99 (Fig. 5).  At 
TA99 doses <~ 150 Ixg, depigmentation was not observed (0 
of 54  mice).  Thus,  the  threshold  dose  of mAb  TA99  re- 
quired for coat color changes was fivefold greater than the 
threshold  required  for antitumor  effects  in  tumor protec- 
tion  experiments.  Histologic  sections  of skin  from  mice 
treated with mAb TA99 showed depigmented hair follicles 
and  regenerating  hairs  in  previously  depilated  areas.  The 
bulbs  of white  hairs  did not contain pigment,  and follicles 
lacked pigmented melanocytes. There were no signs of de- 
crease  in  pigmentation  or pigmented  granules,  inflamma- 
tion, or changes in cellular morphologies or tissue architec- 
ture  in  the  eyes  (choroid and retina)  of mice treated  with 
mAb TA99. There were no detectable alterations in behav- 
ior  or weights  of mice  during  or after  treatment.  In vivo 
depletion with an mAb against Thyl.2 showed that Thyl § 
cells were necessary for depigmentation, but NKI.1 + cells, 
complement,  and  the  individual  CD4 §  or  CD8 §  T  cell 
subsets were not necessary. 
These findings suggest that autoimmunity directed against 
tyrosinase-related  proteins  and other antigens  expressed by 
melanocytes can influence coat color in mice.  This implies 
that  coat color can be  regulated  at  the  level  of a  host re- 
sponse in addition to previously defined genetic controls at 
the cellular level.  The induction of concomitant tumor re- 
jection  and autoimmunity recalls  a  relevant  clinical  obser- 
vation  in persons with  metastatic  melanoma who  develop 
vitiligo.  The  spontaneous  appearance  of vitiligo  has  been 
associated  with  an  improved  prognosis  in  persons  with 
metastatic  melanoma  (25, 26). A  related observation is that 
the immune system of patients  with vitiligo  can recognize 
tyrosinase and other specific antigens expressed by melano- 
cytes (27, 28). This mouse model has recapitulated an asso- 
ciation  between  melanoma  and  vitiligo,  showing  that  a 
Figure 5.  Alteration of coat color in C57BL/6 mice treated with mAb 
TA99. Mice were depilated on day -1 over the left posterior flank and 
abdomen. On day 0, mice started treatment with either mAb TA99 (left 
mouse) or mAb UPC10  (right mouse) three times per week for 2 wk (see 
schedule in Fig. 1) at individual daily doses of  300 ~g. The line demarcat- 
ing the upper border of the shaved coat (dorsal trunk  of the animal)  can be 
seen in the control animal (right mouse).  The coat of mice treated with 
mAb TA99 showed depigmentation in areas of regenerating hairs but not 
in the nondepilated coat, while no alteration in coat color was observed 
in mice treated with isotype control mAb UPC10. 
biologic  response  to  the  tyrosinase  family  of proteins  in 
melanocytes of the skin can mediate melanoma rejection. 
In summary, an increasing body of data suggests that im- 
mune recognition of melanoma in humans is directed most 
frequently  against  molecules  expressed  by melanocytes  or 
other neural  crest-derived  cell  types  (it should be pointed 
out that this perceived "immune  repertoire"  against mela- 
noma  can be  biased  by the  use  of selected  in  vitro  assays 
and  may  not be  a  random  sampling).  These  experiments 
suggest  that  the  threshold  for depigmentation,  a  potential 
autoimmune manifestation,  can be greater than that for tu- 
mor protection,  and that the biologic state  of melanocytes 
may  be  important  in  the  development  of autoimmune 
signs. Passive transfer of mAb against gp75 was able to lead 
to rejection even of established B16F10 tumors in the lung 
(similar  effects  have  been  observed  with  mAb  treatment 
against other antigens expressed by B16F10)  (29). We have 
shown that passive immunity against melanocytes can lead 
to  effective  rejection  of even  established  tumors.  Mela- 
noma is not the only tumor type where differentiation anti- 
gens are recognized by the  immune  system.  Immune rec- 
ognition  of differentiation  antigens  has  also been  detected 
in  patients  with  breast,  colon,  and  pancreas  carcinomas 
(30-32). 
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